reports
- Jacob Mekhael
- Emira Sagaama
- Michael B. Schäfer
SOP SOPRA STERIA GROUP SA
TFI TELEVISION FRANCAISE 1 SA
VETO VETOQUINOL SA
LSS LECTRA SA
EBRO EBRO FOODS SA
MBB MBB INDUSTRIES SE
G24 SCOUT24 AG
ELIS ELIS SA
MAREL MAREL HF.
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
DLG DE'LONGHI S.P.A.
FDR FLUIDRA S.A.
MELE MELEXIS NV
SPIE SPIE SA
GLPG GALAPAGOS NV
IDR INDRA SISTEMAS S.A. CLASS A
UNI UNICAJA BANCO S.A.
DUFN DUFRY AG
RUI RUBIS SCA
ALD ALD SA
BFSA BEFESA SA
VOS VOSSLOH AG
WAVE WAVESTONE SA
CLA CLARANOVA SE
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
FPE3 FUCHS PETROLUB SE
STM STABILUS SE
FLOW FLOW TRADERS LTD
PLX PLUXEE NV
- Emira Sagaama
- Michael B. Schäfer
SOP SOPRA STERIA GROUP SA
TFI TELEVISION FRANCAISE 1 SA
VETO VETOQUINOL SA
LSS LECTRA SA
EBRO EBRO FOODS SA
MBB MBB INDUSTRIES SE
G24 SCOUT24 AG
ELIS ELIS SA
MAREL MAREL HF.
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
DLG DE'LONGHI S.P.A.
FDR FLUIDRA S.A.
MELE MELEXIS NV
SPIE SPIE SA
GLPG GALAPAGOS NV
IDR INDRA SISTEMAS S.A. CLASS A
UNI UNICAJA BANCO S.A.
DUFN DUFRY AG
RUI RUBIS SCA
ALD ALD SA
BFSA BEFESA SA
VOS VOSSLOH AG
WAVE WAVESTONE SA
CLA CLARANOVA SE
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
FPE3 FUCHS PETROLUB SE
STM STABILUS SE
FLOW FLOW TRADERS LTD
PLX PLUXEE NV
- Damien Choplain
- Martial Descoutures
Galapagos : Sharp ramp-up in R&D costs
>A sharp ramp-up in R&D costs - Galapagos reported yesterday its Q3 earnings after the closure of the US market. Revenues stood at € 60m vs € 70m forecast. These revenues come mainly from the booking of its agreement over 10 years with Gilead. In terms of costs, opex ramp up very sharply in the first 9M of the year.The R&D business is developing as expected following the progress in clinical programs, but costs are proving far higher than forecasts with a s...
- Jacob Mekhael
Galapagos Uneventful 9M24 results, new cell therapy data at ASH
Galapagos reported uneventful 9M24 results with a cash position of € 3.3b, and reiterated its FY24 cash burn guidance of € 370-410m (including BD). In the pipeline, we most look forward to new data from the phase 1/2 ATALANTA-1 and EUPLAGIA-1 CAR-T studies at ASH in December 2024, and are keen to see the solid outcomes observed to date confirmed in a larger set of patients and with longer follow up. In addition, the company plans to present pre-clinical data for uza-cel (TCR-T), and we hope to g...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Damien Choplain
- Martial Descoutures
Galapagos : Une accélération forte des frais de R&D
>Une forte accélération des frais de R&D - Galapagos a publié hier ses résultats du T3 après la fermeture du marché US. Les revenus s’élèvent à 60 M€ vs 70 M€ att. Ces revenus viennent essentiellement de la reconnaissance de son accord portée sur 10 ans avec Gilead. Au niveau des couts, les Opex accélèrent très fortement sur les 9premiers mois de l’année.L’activité de R&D se développe logiquement suite aux avancées des programmes cliniques, mais les coûts s...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Bu...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Investi...
Galapagos rapporteert financiële resultaten over het derde kwartaal va...
Galapagos rapporteert financiële resultaten over het derde kwartaal van 2024 en geeft een bedrijfsupdate We bouwen onze pijplijn en versnellen innovatie door gerichte uitvoering van onze Forward, Faster strategie.We streven ernaar te voorzien in de grote onvervulde behoeften van patiënten met onze groeiende pijplijn van celtherapie en kleine moleculen met doorbraakpotentieel. Deze omvat meer dan 20 programma’s, met vier kandidaat-producten in klinische ontwikkeling in 11 indicaties, en meer dan 15 preklinische programma's in oncologie en immunologie. We bereikten een belangrijke regelgevend...
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Hilde Van Boxstael
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
Correction: Syensqo - Participation notification by BlackRock Inc.
Correction: Syensqo - Participation notification by BlackRock Inc. Participation notification by BlackRock Inc. Brussels, Belgium – October 10, 2024 - 8:30 CEST In a release issued on October 10, 2024, please note the following chanages: the shareholder's denomination, the notification date and the reason for the notification were amended. The corrected release follows: According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (12 Throgmorton Avenue, London EC2N 2DL, UK) recently sent Syensqo the following transparency notifications indicating that it cr...
Correction: Syensqo - Participatiemelding van BlackRock Inc.
Correction: Syensqo - Participatiemelding van BlackRock Inc. Participatiemelding van BlackRock Inc. Brussel, België - 10 oktober 2024 – 8u30 CEST In een bericht van 10 oktober 2024 zijn de volgende wijzigingen aangebracht: de benaming van de aandeelhouder, de datum van kennisgeving en de reden voor de kennisgeving zijn gewijzigd. Het gecorrigeerde bericht volgt hieronder: In overeenstemming met de Belgische wetgeving op de openbaring van belangrijke deelnemingen (wet van 2 mei 2007), heeft BlackRock Inc. (12 Throgmorton Avenue, London EC2N 2DL, UK) een transparantiemelding naar S...
Syensqo - Acquisition of own shares
Syensqo - Acquisition of own shares Acquisition of own shares Brussels, Belgium – October 21, 2024 - 17:45 CEST In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) hereby discloses certain information in relation to its Share Buyback Program, announced on 25 June 2024. In the framework of this Share Buyback Program, covering the buyback of a maximum of 983,000 Syensqo shares, Syensqo announces that it has repurchased 66,890 Syensqo shares in the period from 14 October up to...
Syensqo - Acquisition d'actions propres
Syensqo - Acquisition d'actions propres Acquisition d'actions propres Bruxelles, Belgique – 21 octobre 2024 - 17:45 CEST Conformément à l'article 8:4 de l'Arrêté Royal du 29 avril 2019 portant exécution du Code belge des Sociétés et des Associations, Syensqo SA ("Syensqo" ou la "Société") publie certaines informations relatives à son Programme de Rachat d'Actions Propres, annoncé le 25 juin 2024. Dans le cadre de ce Programme de Rachat d'Actions Propres, couvrant l’acquisition d'un maximum de 983 000 actions Syensqo, Syensqo annonce qu'elle a acquis 66.890 actions Syensqo au cours de l...
Syensqo - Verwerving van eigen aandelen
Syensqo - Verwerving van eigen aandelen Verwerving van eigen aandelen Brussel, België - 21 oktober 2024 – 17u45 CEST In overeenstemming met artikel 8:4 van het Koninklijk Besluit van 29 april 2019 tot uitvoering van het Belgisch Wetboek van Vennootschappen en Verenigingen, maakt Syensqo NV (“Syensqo” of de “Vennootschap”) hierbij bepaalde informatie bekend in verband met zijn Aandelen Inkoopprogramma, aangekondigd op 25 juni 2024. In het kader van dit Aandelen Inkoopprogramma, dat voorziet in de inkoop van maximaal 983 000 Syensqo-aandelen, kondigt Syensqo aan dat het 66,890 Syensqo-aan...
- Anthony Dick
- Emira Sagaama
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2024
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
- Anthony Dick
- Emira Sagaama
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2024
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
- Sharad Kumar S.P
Holdings Report - September 2024 Exor Added To The KBC Securities Hold...
1M Performance - Absolute: During Sept'24 (1M period), the KBCS Holdings Universe posted a return of -0.2% which was mainly driven by multi-asset holdings (-1.2%) while single-asset holdings posted a positive return of 2.0%. The 3 top performers during the period were Sofina (+15.3%), Financière de Tubize (+8.4%), and Brederode (+7.2%) while the 3 worst performers were Exor (-4.4%), Compagnie du Bois Sauvage (-5.5%), and D'Ieteren Group (-7.2%). YTD Performance - Relative: On a YTD basis (as o...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
- Cor Kluis
Aegon : Q3 stable solvency and OCG, 14% FCF yield, a new positive SBB ...
>Conclusion: Q3 stable solvency and OCG, a new positive SBB possible - Aegon will present a Q3 trading update in which we expect a stable US RBC ratio and a stable UK Solvency ratio by end-Q3 vs end-Q2. The gross cash capital at holding is expected to be € 1.5bn by end-Q3 24, which is at the top end of their target € 0.5-1.5bn range. We expect qoq a stable OCG before holding/interest costs of € 287m in Q3 24. At the trading update it is possible that Aegon would annou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.